Literature DB >> 27501533

Considerations about the Aspirin and Tranexamic Acid for Coronary Artery Surgery (ATACAS) trial.

Antonino Di Franco1, Mario Gaudino1, Leonard N Girardi1.   

Abstract

Entities:  

Year:  2016        PMID： 27501533      PMCID： PMC4958827          DOI： 10.21037/jtd.2016.05.43

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN： 2072-1439            Impact factor:   2.895


× No keyword cloud information.
  3 in total

1.  Multiple daily doses of acetyl-salicylic acid (ASA) overcome reduced platelet response to once-daily ASA after coronary artery bypass graft surgery: a pilot randomized controlled trial.

Authors:  J S Paikin; J Hirsh; J S Ginsberg; J I Weitz; N C Chan; R P Whitlock; G Pare; M Johnston; J W Eikelboom
Journal:  J Thromb Haemost       Date:  2015-02-06       Impact factor: 5.824

2.  Stopping vs. Continuing Aspirin before Coronary Artery Surgery.

Authors:  Paul S Myles; Julian A Smith; Andrew Forbes; Brendan Silbert; Mohandas Jayarajah; Thomas Painter; D James Cooper; Silvana Marasco; John McNeil; Jean S Bussières; Sophie Wallace
Journal:  N Engl J Med       Date:  2016-02-25       Impact factor: 91.245

3.  Reappraisal of the clinical pharmacology of low-dose aspirin by comparing novel direct and traditional indirect biomarkers of drug action.

Authors:  P Patrignani; S Tacconelli; E Piazuelo; L Di Francesco; M Dovizio; C Sostres; E Marcantoni; P Guillem-Llobat; P Del Boccio; M Zucchelli; C Patrono; A Lanas
Journal:  J Thromb Haemost       Date:  2014-07-18       Impact factor: 5.824
  3 in total
  1 in total

Review 1.  Antiplatelet agents for chronic kidney disease.

Authors:  Patrizia Natale; Suetonia C Palmer; Valeria M Saglimbene; Marinella Ruospo; Mona Razavian; Jonathan C Craig; Meg J Jardine; Angela C Webster; Giovanni Fm Strippoli
Journal:  Cochrane Database Syst Rev       Date:  2022-02-28
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.